Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial

Background  The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic venous thromboembolism (VTE) or VTE-related death in acutely ill medical patients at risk for VTE. Although aspirin use was not randomized, approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Spyropoulos, Alex C., Goldin, Mark, Ageno, Walter, Albers, Gregory W., Elliott, C. Gregory, Hiatt, William R., Halperin, Jonathan L., Maynard, Gregory, Steg, P. Gabriel, Weitz, Jeffrey I., Spiro, Theodore E., Lu, Wentao, Marsigliano, Jessica, Raskob, Gary E., Barnathan, Elliot S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273326/
https://www.ncbi.nlm.nih.gov/pubmed/36046208
http://dx.doi.org/10.1055/s-0042-1750379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273326/
https://www.ncbi.nlm.nih.gov/pubmed/36046208
http://dx.doi.org/10.1055/s-0042-1750379

Ejemplares similares